Silencing Survivin Splice Variant 2B Leads to Antitumor Activity in Taxane-Resistant Ovarian Cancer
Open Access
- 1 June 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (11), 3716-3726
- https://doi.org/10.1158/1078-0432.ccr-11-0233
Abstract
Purpose: To study the role of survivin and its splice variants in taxane-resistant ovarian cancer. Experimental Design: We assessed the mRNA levels of survivin splice variants in ovarian cancer cell lines and ovarian tumor samples. siRNAs targeting survivin were designed to silence all survivin splice variants (T-siRNA) or survivin 2B (2B-siRNA) in vitro and orthotopic murine models of ovarian cancer. The mechanism of cell death was studied in taxane-resistant ovarian cancer cells and in tumor sections obtained from different mouse tumors. Results: Taxane-resistant ovarian cancer cells express higher survivin mRNA levels than their taxane-sensitive counterparts. Survivin 2B expression was significantly higher in taxane-resistant compared with -sensitive cells. Silencing survivin 2B induced growth inhibitory effects similar to silencing total survivin in vitro. In addition, survivin 2B-siRNA incorporated into DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) nanoliposomes resulted in significant reduction in tumor growth (P < 0.05) in orthotopic murine models of ovarian cancer, and these effects were similar to T-siRNA-DOPC. The antitumor effects were further enhanced in combination with docetaxel chemotherapy (P < 0.01). Finally, we found a significant association between survivin 2B expression and progression-free survival in 117 epithelial ovarian cancers obtained at primary debulking surgery. Conclusions: These data identify survivin 2B as an important target in ovarian cancer and provide a translational path forward for developing new therapies against this target. Clin Cancer Res; 17(11); 3716–26. ©2011 AACR.Keywords
Other Versions
This publication has 50 references indexed in Scilit:
- Sustained Small Interfering RNA Delivery by Mesoporous Silicon ParticlesCancer Research, 2010
- Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymersMolecular Cancer, 2009
- Therapeutic Targeting of ATP7B in Ovarian CarcinomaClinical Cancer Research, 2009
- Dicer, Drosha, and Outcomes in Patients with Ovarian CancerNew England Journal of Medicine, 2008
- Deconstructing Survivin: comprehensive genetic analysis of Survivin function by conditional knockout in a vertebrate cell lineThe Journal of cell biology, 2008
- Clinical and Biological Significance of Tissue Transglutaminase in Ovarian CarcinomaCancer Research, 2008
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- Targeting survivin in cancer therapyEmerging Therapeutic Targets, 2008
- Forced Expression of Survivin-2B Abrogates Mitotic Cells and Induces Mitochondria-dependent Apoptosis by Blockade of Tubulin Polymerization and Modulation of Bcl-2, Bax, and SurvivinJournal of Biological Chemistry, 2007
- Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma TherapyClinical Cancer Research, 2006